The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
N-(3-(4-isopropoxy-6-(4-(4-methylpiperazin-1-yl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl)acrylamide ID: ALA4799276
Chembl Id: CHEMBL4799276
PubChem CID: 162676678
Max Phase: Preclinical
Molecular Formula: C29H32N6O2
Molecular Weight: 496.62
Molecule Type: Unknown
Associated Items:
Names and Identifiers Canonical SMILES: C=CC(=O)Nc1cccc(-c2c(-c3ccc(N4CCN(C)CC4)cc3)[nH]c3ncnc(OC(C)C)c23)c1
Standard InChI: InChI=1S/C29H32N6O2/c1-5-24(36)32-22-8-6-7-21(17-22)25-26-28(30-18-31-29(26)37-19(2)3)33-27(25)20-9-11-23(12-10-20)35-15-13-34(4)14-16-35/h5-12,17-19H,1,13-16H2,2-4H3,(H,32,36)(H,30,31,33)
Standard InChI Key: SNPHORMIAYSVQZ-UHFFFAOYSA-N
Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 496.62Molecular Weight (Monoisotopic): 496.2587AlogP: 4.96#Rotatable Bonds: 7Polar Surface Area: 86.38Molecular Species: NEUTRALHBA: 6HBD: 2#RO5 Violations: ┄HBA (Lipinski): 8HBD (Lipinski): 2#RO5 Violations (Lipinski): ┄CX Acidic pKa: 11.70CX Basic pKa: 7.85CX LogP: 4.89CX LogD: 4.28Aromatic Rings: 4Heavy Atoms: 37QED Weighted: 0.35Np Likeness Score: -1.05
References 1. Lategahn J,Hardick J,Grabe T,Niggenaber J,Jeyakumar K,Keul M,Tumbrink HL,Becker C,Hodson L,Kirschner T,Klövekorn P,Ketzer J,Baumann M,Terheyden S,Unger A,Weisner J,Müller MP,van Otterlo WAL,Bauer S,Rauh D. (2020) Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach., 63 (20.0): [PMID:32931277 ] [10.1021/acs.jmedchem.0c00870 ] 2. Shaikh M, Shinde Y, Pawara R, Noolvi M, Surana S, Ahmad I, Patel H.. (2022) Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer., 65 (2.0): [PMID:34323489 ] [10.1021/acs.jmedchem.1c00876 ]